Close Menu

Tom Lindsay

Apr 09, 2018

Genedrive has appointed Tom Lindsay as a non-executive director, effective immediately. Lindsay most recently was at Alere, where he held roles including president of Africa, president of commercial operations in Africa, and business development director for Africa, before he retired in 2017. Prior to Alere, he held senior commercial roles at Trinity Biotech. 

More Like This

Aug 16, 2019

Yourgene: Jonathan Seaton

Yourgene has appointed Jonathan Seaton to its board of directors as a non-executive director. Seaton is currently serves as director at GenomOncology. Prior to that, he served as head of corporate and business development and government affairs at Becton Dickinson. Before Becton Dickinson, Seaton served as vice director, global business development at Roche Diagnostics from 2008-2015. Prior to Roche, he worked as a life sciences investment banker for Deutsche Bank. 

Aug 15, 2019

Aperiomics: C. Alexander Valencia

C. Alexander Valencia has joined Aperiomics as Chief Clinical Officer. He will oversee the microorganism sequencing firm's clinical test development, validations, regulatory affairs, and operations.

Prior to joining Aperiomics, Valencia served as molecular laboratory director at Cincinnati Children's Hospital Medical Center. He has experience at PerkinElmer Genomics. He holds a doctorate from Canada's Carleton University and the University of Ottawa and held post-doctoral positions in biochemistry and molecular biology at the University of North Carolina at Chapel Hill and in clinical molecular genetics at Emory University.

Aug 14, 2019

OraSure Technologies: James Datin

OraSure Technologies has appointed James Datin to its board. He will serve as a Class III director with his initial term expiring at the company's 2021 shareholders' meeting. He will serve on OraSure's audit and compensation committees. Datin is president and CEO of BioAgilytix, a global bioanalytical contract research organization which supports the development of therapeutic biologics. Prior to that, he was executive vice president and managing director at Safeguard Scientifics. 

Aug 13, 2019

Biodesix: Robert Georgantas III

Robert Georgantas III was appointed by Biodesix as its senior vice president of research and translational science. He was formerly director of immunology programs, genomics, and the Genetics Research Center of Excellence at AbbVie. Prior to that, he was a senior scientist in the department of translational sciences at Medimmune. 

Aug 09, 2019

NeoGenomics: Sharon Virag

NeoGenomics said in a document filed with the US Securities and Exchange Commission that CFO Sharon Virag has resigned from the company, effective immediately. NeoGenomics did not provide additional details. It will begin a search for her replacement "in due course," it said.

Aug 07, 2019

Progenity: Brian Kotzin

Progenity has appointed Brian Kotzin to its board of directors. Kotzin is currently on the board of directors for Rigel, and serves as a principal fellow and senior vice president for Nektar Therapeutics. His previous roles include vice president of global clinical development and head of the inflammation therapeutic area, and vice president and head of medical sciences at Amgen. Prior to entering the life sciences industry, he held several professorships at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease.

Aug 07, 2019

Oxford Nanopore Technologies: John Schoellerman

John Schoellerman has joined Oxford Nanopore Technologies as senior vice president of corporate development and investment. Previously, he was managing director and head of medtech at Lazard, and before that, he worked in healthcare investment banking at JP Morgan. Schoellerman holds a BA from Harvard University and an MBA from INSEAD.

Aug 06, 2019

Invitae: Randy Scott, Sean George

Invitae announced that Randy Scott will retire as executive chairman from its board of directors effective September 1. Invitae CEO Sean George will be the board's new chairman at that time. Scott served as CEO of Invitae between 2012 and 2017, after which George took over the reins. Scott said in a statement that he plans to continue to support the Invitae team as a private investor.

Aug 06, 2019

Serimmune: Noah Nasser, Bill Welch

Goleta, California-based Serimmune has appointed Noah Nasser as CEO and Bill Welch to its board of directors.

Prior to Seriummne, Nasser served as chief commercial officer at Human Longevity. Before working at Human Longevity, Nasser served as chief commercial officer at Counsyl. In addition, he held leadership positions at AltheaDx and Verinata Health. 

Welch is currently a venture partner at Illumina Ventures. Before joining Illumina Ventures, Welch served as CEO at Trovagene. Prior to Trovagene, Welch was president and CEO at Sequenom. Before working at Sequenom, Welch served as CCO at Monogram Biosciences. Prior to Monogram, Welch held progressive management positions at Abbot Laboratories. 

Aug 05, 2019

Foundation Medicine: Priti Hegde

Priti Hegde has been appointed as CSO of Foundation Medicine, a Roche company, effective August 5. She replaces Michael Doherty, who will be retiring in September. Previously, she held various posts at Genentech, where she was most recently senior director and principal scientist in oncology biomarker development. Prior to that, she was manager of disease and biomarker transcriptomics at GlaxoSmithKline. Hegde holds a PhD in biochemical pharmacology from SUNY Buffalo and a B. Pharmacy degree from Mumbai University in India.

Aug 05, 2019

Roche Diagnostics Canada: Andrew Plank

Andrew Plank has been appointed as president and general manager of Roche Diagnostics Canada, a division of Roche. Previously, he was global VP and international business leader in Roche Diagnostics' Centralized and Point of Care Solutions division in Switzerland.

Aug 05, 2019

Fulgent Genetics: Linda Marsh

Temple City, California-based Fulgent Genetics has appointed Linda Marsh to its board of directors. Marsh currently serves as senior executive VP at AHMC Healthcare and is a board member at Apollo Medical Holdings. In addition, she is a board member of the Hospital Association of Southern California, a board member of Private Essential Access Community Hospitals, and a board member of the American Red Cross.

Aug 01, 2019

Fluidigm: Jonathan Day

Fluidigm has appointed Jonathan Day as VP of commercial operations, Americas. Day was most recently VP of sales and support, Americas, for Agena Bioscience. Previously, he held roles of increasing responsibility at Thermo Fisher Scientific. Day also previously worked for Affymetrix.

Aug 01, 2019

Thrive: David Daly

Thrive has appointed David Daly as CEO and to its board of directors. Daly joins the firm with more than 25 years of leadership. Prior to Thrive, Daly served as senior VP and general manager of commercial operations at Illumina. Prior to Illumina, Daly served as general manager and chief commercial officer at Foundation Medicine. Before working at Foundation Medicine, Daly led the oncology business unit at Life Technologies, served as CCO at Clarient, and held roles at Roche Diagnostics and Abbott Laboratories.

Jul 30, 2019

Genomics England: Chris Wigley

Chris Wigley has been appointed as CEO of Genomics England, effective October 1. He will replace current interim CEO Sir Mark Caulfield, who will remain the firm's chief scientist. Wigley will join Genomics England, which is wholly owned by the UK's Department of Health & Social Care, from QuantumBlack, a machine learning and artificial intelligence company, where he was chief operating officer. Prior to that, he was a partner at McKinsey, and before that, a diplomat with the British Foreign Office.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.